|
|
| (5 intermediate revisions by 3 users not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Esmolol#Adult Indications and Dosage]] |
| {{Esmolol}}
| |
| {{CMG}}; {{AE}} {{AZ}}
| |
| | |
| ==Indications And Usage==
| |
| | |
| ===Supraventricular Tachycardia or Noncompensatory Sinus Tachycardia===
| |
| BREVIBLOC (Esmolol Hydrochloride) is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. BREVIBLOC is also indicated in noncompensatory sinus tachycardia where, in the physician’s judgment, the rapid heart rate requires specific intervention. BREVIBLOC is intended for short-term use.
| |
| | |
| ===Intraoperative and Postoperative Tachycardia and/or Hypertension===
| |
| BREVIBLOC (Esmolol Hydrochloride) is indicated for the short-term treatment of tachycardia and hypertension that occur during induction and tracheal intubation, during surgery, on emergence from anesthesia and in the postoperative period, when in the physician’s judgment such specific intervention is considered indicated.
| |
| | |
| Use of BREVIBLOC to prevent such events is not recommended.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = BREVIBLOC (ESMOLOL HYDROCHLORIDE) INJECTION [BAXTER HEALTHCARE CORPORATION] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=595cc3d5-1306-4828-aefa-5595219ffd62 | publisher = | date = | accessdate = }}</ref>
| |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
|
| |
|
| | [[Category:Beta blockers]] |
| | [[Category:Cardiovascular Drugs]] |
| [[Category:Drugs]] | | [[Category:Drugs]] |